Abstract

Cognitive decline is a major health concern and identification of genes that may serve as drug targets to slow decline is important to adequately support an aging population. Whilst genetic studies of cross-sectional cognition have been carried out, cognitive change is less well-understood. Here, using data from the TOMMORROW trial, we investigate genetic associations with cognitive change in a cognitively normal older cohort. We conducted a genome-wide association study of trajectories of repeated cognitive measures (using generalised estimating equation (GEE) modelling) and tested associations with polygenic risk scores (PRS) of potential risk factors. We identified two genetic variants associated with change in attention domain scores, rs534221751 (p = 1 × 10−8 with slope 1) and rs34743896 (p = 5 × 10−10 with slope 2), implicating NCAM2 and CRIPT/ATP6V1E2 genes, respectively. We also found evidence for the association between an education PRS and baseline cognition (at >65 years of age), particularly in the language domain. We demonstrate the feasibility of conducting GWAS of cognitive change using GEE modelling and our results suggest that there may be novel genetic associations for cognitive change that have not previously been associated with cross-sectional cognition. We also show the importance of the education PRS on cognition much later in life. These findings warrant further investigation and demonstrate the potential value of using trial data and trajectory modelling to identify genetic variants associated with cognitive change.

Details

Title
Investigation of genetic determinants of cognitive change in later life
Author
Mahedy, Liam 1   VIAFID ORCID Logo  ; Anderson, Emma L. 1 ; Tilling, Kate 2 ; Thornton, Zak A. 1 ; Elmore, Andrew R. 2   VIAFID ORCID Logo  ; Szalma, Sándor 3   VIAFID ORCID Logo  ; Simen, Arthur 4 ; Culp, Meredith 4 ; Zicha, Stephen 4 ; Harel, Brian T. 4 ; Davey Smith, George 2   VIAFID ORCID Logo  ; Smith, Erin N. 3 ; Paternoster, Lavinia 2   VIAFID ORCID Logo 

 University of Bristol, MRC Integrative Epidemiology Unit, Bristol, UK (GRID:grid.5337.2) (ISNI:0000 0004 1936 7603); University of Bristol, Department of Population Health Sciences, Bristol Medical School, Bristol, UK (GRID:grid.5337.2) (ISNI:0000 0004 1936 7603) 
 University of Bristol, MRC Integrative Epidemiology Unit, Bristol, UK (GRID:grid.5337.2) (ISNI:0000 0004 1936 7603); University of Bristol, Department of Population Health Sciences, Bristol Medical School, Bristol, UK (GRID:grid.5337.2) (ISNI:0000 0004 1936 7603); NHS Foundation Trust and University of Bristol, NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston, Bristol, UK (GRID:grid.511076.4) 
 Takeda Development Center Americas, Inc., San Diego, USA (GRID:grid.419849.9) (ISNI:0000 0004 0447 7762) 
 Takeda Development Center Americas, Inc., Cambridge, USA (GRID:grid.419849.9) (ISNI:0000 0004 0447 7762) 
Pages
31
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
21583188
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2916273717
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.